17635-45-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(1H-Pyrazol-1-yl)aniline is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(1H-Pyrazol-1-yl)aniline serves as a precursor in the production of agrochemicals, aiding in the creation of compounds that protect crops and enhance agricultural productivity.
Used in Dye Industry:
4-(1H-Pyrazol-1-yl)aniline is utilized as an intermediate in the synthesis of dyes, playing a role in the coloration of various materials for industrial and commercial applications.
Used in Rubber Chemicals Production:
4-(1H-Pyrazol-1-yl)aniline is used as a component in the manufacturing of rubber chemicals, which are essential for improving the performance and durability of rubber products.
Used in UV Stabilizers Production:
It is also employed in the production of UV stabilizers, which are crucial for protecting materials from the degrading effects of ultraviolet radiation, thus extending their lifespan and maintaining their integrity.
Safety and Environmental Considerations:
Due to its potential hazards, including skin, eye, and respiratory system irritation, 4-(1H-Pyrazol-1-yl)aniline should be handled with care. Additionally, proper management is necessary to mitigate any environmental risks associated with its use and disposal.

InChI:InChI=1/C9H9N3/c10-8-2-4-9(5-3-8)12-7-1-6-11-12/h1-7H,10H2

Upstream product

• 288-13-1 NH-pyrazole 
• 106-40-1 4-bromo-aniline 
• 540-37-4 p-aminoiodobenzene 
• 106-47-8 4-chloro-aniline 
• 636-98-6 p-nitrobenzene iodide 
• 1126-00-7 1-phenylpyrazole 
• 100-16-3 4-nitrophenylhydrazone 
• 350-46-9 4-Fluoronitrobenzene 
• 3463-30-7 1-(4-nitrophenyl)pyrazole 

Downstream Products

• 352018-96-3 4-(1H-pyrazol-1-yl)phenyl isothiocyanate 
• 926907-42-8 2-cyano-2-(4-pyrazol-1-yl-phenylthiocarbamoyl)-acetamide 
• 926907-50-8 3-hydroxy-5-(4-pyrazol-1-yl-phenylamino)-isothiazole-4-carbonitrile 
• 76457-93-7 (4-Pyrazol-1-yl-phenylamino)-acetic acid 
• 76457-94-8 2-(4-Pyrazol-1-yl-phenylamino)-propionic acid 
• 76458-01-0 C₁₁H₁₀N₄O₃ 
• 76458-02-1 C₁₂H₁₂N₄O₃ 
• 76458-10-1 3-phenylsydnone 
• 76457-95-9 Phenyl-(4-pyrazol-1-yl-phenylamino)-acetic acid 
• 76458-11-2 C₁₂H₁₀N₄O₂ 
• 76458-03-2 C₁₇H₁₄N₄O₃ 
• 76458-12-3 C₁₇H₁₂N₄O₂ 
• 251371-48-9 1-isopropyl-7-[4-(pyrazol-1-yl)phenylamino]-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2(1H)-one 
• 251369-94-5 1-methyl-7-[4-(pyrazol-1-yl)phenylamino]-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2(1H)-one 

Relevant academic research and scientific papers

Solvent-free preparation of tris-pyrazolyl-1,3,5-triazines

Tris-pyrazolyl-1,3,5-triazines have been prepared by cyclotrimerization of aromatic nitriles in solvent-free conditions. The interesting structures of these compounds make them candidates for application in coordination chemistry and crystal engineering.

Bismuth(III)-SiO2 catalyzed synthesis of polysubstituted imidazoles with the participation of azaaryl derivatives of aniline in four-component reactions

A series of novel polyaromatic derivatives of imidazole were synthesized by Bi(III) nitrate-SiO2 catalyzed four-component reactions of benzil, ammonium acetate, aromatic aldehydes, and N -heterocyclic derivatives of aniline under solvent-free c

Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors

Through a structure-based drug design approach, a tricyclic benzonaphthyridinone pharmacophore was used as a starting point for carrying out detailed medicinal structure-activity relationhip (SAR) studies geared toward characterization of a panel of propo

NEW BRUTON'S TYROSINE KINASE INHIBITOR

The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceu

QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders a

Carbon nitride supported palladium nanoparticles: An active system for the reduction of aromatic nitro-compounds

Synthesis of carbon nitride supported highly dispersed ultrafine palladium nanoparticles has been reported for the reduction of aromatic nitro-compounds using hydrazine hydrate as a reducing agent. As a demonstration, the as-synthesized carbon nitride-palladium composite was shown to be a highly active and chemo-selective for the title reaction. Utilizing the optimized reaction conditions a set of aromatic nitro compounds have been converted to their corresponding amine derivatives with good to excellent yield ranging from 80% to 99%. The catalyst can be used for multiple times without affecting the catalytic performance and can also be stored for a long time at ambient condition maintaining the high catalytic efficiency.

6-substituted pyrazolyl quinazolinone compound and use thereof

The invention discloses a 6-substituted pyrazolyl quinazolinone compound which is represented by a formula I shown in the description or a salt of the compound represented by the formula I. The compound I represented by the formula I has excellent insecti

IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES

Formula IA, ad their use for treating viral infections.

Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof

A five-and-six-membered heterocyclic compound as represented by general formula I, pharmaceutically acceptable salt, metabolite, metabolic precursors or drug precursors thereof, preparation method, pharmaceutical composition, and use thereof; the five-and-six-membered heterocyclic compound has activity as a Janus kinase (JAK) inhibitor, and can be used to prepare drugs for treating diseases caused by the abnormal activity of kinase, such as cell proliferation diseases like cancer.

Ligand-free N-arylation of heterocycles using metal-organic framework [Cu(INA)2] as an efficient heterogeneous catalyst

A metal-organic framework [Cu(INA)2] was synthesized and used as a heterogeneous catalyst for arylation of a wide range of N-H heterocycles and aryl halides under ligand-free conditions. The N-arylation reaction involved the use of 5 mol% Cu-MOF catalyst with K3PO4 or tBuOLi as the base in dimethylacetamide (DMA) solvent at 100 °C in 6 h. [Cu(INA)2] exhibited higher catalytic activity for the N-arylation transformation than that of common homogeneous copper catalysts and other Cu-MOFs with unsaturated open metal sites such as Cu2(BDC)2(BPY), Cu3(BTC)2, and Cu2(BDC)2(DABCO). Interestingly, reaction conditions are compatible with a wide range of N-H heterocycles, functional groups, and aryl chlorides. A leaching test indicated no contribution of leached active species in the reaction filtrate. Furthermore, the [Cu(INA)2] catalyst could be facilely separated from the reaction mixture and recovered and reused several times without a significant degradation in catalytic activity.